264 related articles for article (PubMed ID: 22619538)
1. Peptide-modified liposomes for selective targeting of bombesin receptors overexpressed by cancer cells: a potential theranostic agent.
Accardo A; Salsano G; Morisco A; Aurilio M; Parisi A; Maione F; Cicala C; Tesauro D; Aloj L; De Rosa G; Morelli G
Int J Nanomedicine; 2012; 7():2007-17. PubMed ID: 22619538
[TBL] [Abstract][Full Text] [Related]
2. Bombesin peptide antagonist for target-selective delivery of liposomal doxorubicin on cancer cells.
Accardo A; Mansi R; Salzano G; Morisco A; Aurilio M; Parisi A; Maione F; Cicala C; Ziaco B; Tesauro D; Aloj L; De Rosa G; Morelli G
J Drug Target; 2013 Apr; 21(3):240-249. PubMed ID: 23167653
[TBL] [Abstract][Full Text] [Related]
3. Receptor-binding, biodistribution, dosimetry, and micro-SPECT/CT imaging of 111In-[DTPA(1), Lys(3), Tyr(4)]-bombesin analog in human prostate tumor-bearing mice.
Ho CL; Chen LC; Lee WC; Chiu SP; Hsu WC; Wu YH; Yeh CH; Stabin MG; Jan ML; Lin WJ; Lee TW; Chang CH
Cancer Biother Radiopharm; 2009 Aug; 24(4):435-43. PubMed ID: 19694578
[TBL] [Abstract][Full Text] [Related]
4. In vitro demonstration of enhanced prostate cancer toxicity: pretargeting with Bombesin bispecific complexes and targeting with polymer-drug-conjugates.
Patil V; Gada K; Panwar R; Majewski S; Tekabe Y; Varvarigou A; Khaw BA
J Drug Target; 2013 Dec; 21(10):1012-21. PubMed ID: 23863118
[TBL] [Abstract][Full Text] [Related]
5. Easy formulation of liposomal doxorubicin modified with a bombesin peptide analogue for selective targeting of GRP receptors overexpressed by cancer cells.
Accardo A; Mannucci S; Nicolato E; Vurro F; Diaferia C; Bontempi P; Marzola P; Morelli G
Drug Deliv Transl Res; 2019 Feb; 9(1):215-226. PubMed ID: 30569349
[TBL] [Abstract][Full Text] [Related]
6. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity.
Teymouri M; Badiee A; Golmohammadzadeh S; Sadri K; Akhtari J; Mellat M; Nikpoor AR; Jaafari MR
Int J Pharm; 2016 Sep; 511(1):236-244. PubMed ID: 27363937
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer targeted chemotherapy based on doxorubicin-loaded bombesin peptide modified nanocarriers.
Wang C; Sun X; Wang K; Wang Y; Yang F; Wang H
Drug Deliv; 2016 Oct; 23(8):2697-2702. PubMed ID: 26203692
[TBL] [Abstract][Full Text] [Related]
8. Target selective micelles for bombesin receptors incorporating Au(III)-dithiocarbamato complexes.
Ringhieri P; Iannitti R; Nardon C; Palumbo R; Fregona D; Morelli G; Accardo A
Int J Pharm; 2014 Oct; 473(1-2):194-202. PubMed ID: 25014371
[TBL] [Abstract][Full Text] [Related]
9. A simple passive equilibration method for loading carboplatin into pre-formed liposomes incubated with ethanol as a temperature dependent permeability enhancer.
Wehbe M; Malhotra A; Anantha M; Roosendaal J; Leung AWY; Plackett D; Edwards K; Gilabert-Oriol R; Bally MB
J Control Release; 2017 Apr; 252():50-61. PubMed ID: 28286316
[TBL] [Abstract][Full Text] [Related]
10. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide.
Chen X; Wang X; Wang Y; Yang L; Hu J; Xiao W; Fu A; Cai L; Li X; Ye X; Liu Y; Wu W; Shao X; Mao Y; Wei Y; Chen L
J Control Release; 2010 Jul; 145(1):17-25. PubMed ID: 20307599
[TBL] [Abstract][Full Text] [Related]
11. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
[TBL] [Abstract][Full Text] [Related]
12. Design, preparation, in vitro and in vivo evaluation of (99m)Tc-N2S2-Tat(49-57)-bombesin: a target-specific hybrid radiopharmaceutical.
Santos-Cuevas CL; Ferro-Flores G; Arteaga de Murphy C; Ramírez Fde M; Luna-Gutiérrez MA; Pedraza-López M; García-Becerra R; Ordaz-Rosado D
Int J Pharm; 2009 Jun; 375(1-2):75-83. PubMed ID: 19393305
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II.
Kahán Z; Sun B; Schally AV; Arencibia JM; Cai RZ; Groot K; Halmos G
Cancer; 2000 Mar; 88(6):1384-92. PubMed ID: 10717621
[TBL] [Abstract][Full Text] [Related]
14. A study on the role of cholesterol and phosphatidylcholine in various features of liposomal doxorubicin: From liposomal preparation to therapy.
Farzaneh H; Ebrahimi Nik M; Mashreghi M; Saberi Z; Jaafari MR; Teymouri M
Int J Pharm; 2018 Nov; 551(1-2):300-308. PubMed ID: 30243944
[TBL] [Abstract][Full Text] [Related]
15. In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215.
Plonowski A; Nagy A; Schally AV; Sun B; Groot K; Halmos G
Int J Cancer; 2000 Nov; 88(4):652-7. PubMed ID: 11058885
[TBL] [Abstract][Full Text] [Related]
16. RC-3095, a gastrin-releasing peptide receptor antagonist, synergizes with gemcitabine to inhibit the growth of human pancreatic cancer CFPAC-1 in vitro and in vivo.
Hong SK; Yang SY; Yin SH; Yang KX
Pancreas; 2014 Jan; 43(1):15-21. PubMed ID: 24326363
[TBL] [Abstract][Full Text] [Related]
17. Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice.
Jungwirth A; Galvan G; Pinski J; Halmos G; Szepeshazi K; Cai RZ; Groot K; Schally AV
Prostate; 1997 Aug; 32(3):164-72. PubMed ID: 9254895
[TBL] [Abstract][Full Text] [Related]
18. Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins.
Engel JB; Schally AV; Halmos G; Baker B; Nagy A; Keller G
Endocr Relat Cancer; 2005 Dec; 12(4):999-1009. PubMed ID: 16322338
[TBL] [Abstract][Full Text] [Related]
19. Targeting GRP receptor: Design, synthesis and preliminary biological characterization of new non-peptide antagonists of bombesin.
Palmioli A; Nicolini G; Tripodi F; Orsato A; Ceresa C; Donzelli E; Arici M; Coccetti P; Rocchetti M; La Ferla B; Airoldi C
Bioorg Chem; 2021 Apr; 109():104739. PubMed ID: 33626451
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo evaluation of a 64Cu-labeled NOTA-Bn-SCN-Aoc-bombesin analogue in gastrin-releasing peptide receptor expressing prostate cancer.
Craft JM; De Silva RA; Lears KA; Andrews R; Liang K; Achilefu S; Rogers BE
Nucl Med Biol; 2012 Jul; 39(5):609-16. PubMed ID: 22261146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]